Harry L Janssen
Overview
Explore the profile of Harry L Janssen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janssen H, Lim Y, Kim H, Sowah L, Tseng C, Coffin C, et al.
JHEP Rep
. 2024 Jan;
6(2):100975.
PMID: 38274492
Background & Aims: Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated...
2.
Sonneveld M, Chiu S, Park J, Brakenhoff S, Kaewdech A, Seto W, et al.
Gastroenterology
. 2023 Sep;
166(1):168-177.e8.
PMID: 37769952
Background & Aims: Patients who discontinue nucleo(s)tide analogue therapy are at risk of viral rebound and severe hepatitis flares, necessitating intensive off-treatment follow-up. Methods: We studied the association between hepatitis...
3.
Pavlovic V, Yang L, Chan H, Hou J, Janssen H, Kao J, et al.
Antivir Ther
. 2019 Mar;
24(2):133-140.
PMID: 30865588
Background: Peginterferon alfa-2a (PEG-IFN) treatment stopping rules in chronic hepatitis B (CHB) are clinically desirable. Previous studies exploring this topic contained important limitations resulting in inconsistent recommendations within the current...
4.
van Tilborg M, Al Marzooqi S, Wong W, Maan R, Vermehren J, Maasoumy B, et al.
Lancet Gastroenterol Hepatol
. 2018 Oct;
3(12):856-864.
PMID: 30274834
Background: Direct-acting antivirals for chronic hepatitis C (HCV) infection have reduced the need for on-treatment HCV RNA monitoring. We assessed the accuracy and cost implications of using HCV core antigen...
5.
van Vlerken L, Arends P, Lieveld F, Arends J, Brouwer W, Siersema P, et al.
Dig Liver Dis
. 2015 May;
47(7):577-83.
PMID: 25936691
Background: Real-life prospective data on adherence to nucleos(t)ide analogues in chronic hepatitis B patients are scarce. Aims: We investigated adherence to entecavir in relation to virological response. Methods: In this...
6.
Si-Ahmed S, Pradat P, Zoutendijk R, Buti M, Mallet V, Cruiziat C, et al.
Antiviral Res
. 2011 Jul;
92(1):90-5.
PMID: 21767570
Background And Aims: The combination of tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) is used extensively to treat HIV infection and also has potent activity against hepatitis B virus (HBV)...
7.
Leemans W, Niesters H, van der Eijk A, Janssen H, Schalm S, de Man R
Eur J Gastroenterol Hepatol
. 2008 Jul;
20(8):773-7.
PMID: 18617782
Background And Objective: Entecavir has potent activity against hepatitis B virus. Drug resistance has not been reported in nucleoside-naïve patients and is low in lamivudine-refractory patients. Methods And Results: A...
8.
Sprengers D, Stoop J, Binda R, Kusters J, Haagmans B, Carotenuto P, et al.
Antivir Ther
. 2007 Nov;
12(7):1087-96.
PMID: 18018767
Background: Treatment with interferon-alpha (IFN-alpha) leads to a response in only a minority of patients with chronic hepatitis B virus (HBV) infection, but the reasons for this are poorly understood....